Experienced in Melanoma

Lionnel Geoffrois

Nancy, FR 
Experienced in Melanoma
Nancy, FR 
OverviewLocationsClinical Research

Overview

Lionnel Geoffrois practices in Nancy, France. Geoffrois is rated as an Experienced expert by MediFind in the treatment of Melanoma. Their top areas of expertise are Renal Cell Carcinoma (RCC), Head and Neck Squamous Cell Carcinoma (HNSCC), Testicular Cancer, Nephrectomy, and Laryngectomy.

Their clinical research consists of co-authoring 62 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 5 articles in the study of Melanoma.

Locations

Nancy, France
Other Locations
Vandoeuvre-les-nancy, France
54519, France
INSERM UMR 1068, St. Quentin En Yvelines All In France, Saint-quentin-sur-indrois, France
Carcinologie Cervicofaciale, 2, Boulevard Tonnellé, Tours, 37000, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug, Procedure
Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
Multicenter Phase II Study of Axitinib in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Multicenter Phase II Study of Axitinib in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Enrollment Status: Completed
Publish Date: September 06, 2022
Intervention Type: Drug
Study Phase: Phase 2
TPExtreme: Randomized, Controlled Trial of Platinum-Cetuximab Combined Either With Docetaxel (TPEx) or With 5FU (Extreme) in Patients With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck
TPExtreme: Randomized, Controlled Trial of Platinum-Cetuximab Combined Either With Docetaxel (TPEx) or With 5FU (Extreme) in Patients With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck
Enrollment Status: Completed
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drugs: Cisplatin, 5-Fluorouracile, Docetaxel, Cetuximab, Granulocyte Colony-Stimulating Factor (G-CSF)
Study Phase: Phase 2
View 3 Less Clinical Trials

62 Total Publications

The UNI-AJA Project: A Feasibility Study Based on Real-World Data in French Adolescents and Young Adults with Cancer.
The UNI-AJA Project: A Feasibility Study Based on Real-World Data in French Adolescents and Young Adults with Cancer.
Journal: Journal of adolescent and young adult oncology
Published: July 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Geoffrois's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile